Targeted cell therapy for tough lupus with kidney involvement
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have lupus nephritis (kidney inflammation from lupus) that has not responded well to standard treatments or has come back after getting better.
- Your lupus is currently active, with a score of 8 or more on a disease activity scale or signs of kidney inflammation.
- Your immune B cells have a specific protein (CD19 or BCMA) that the study treatment targets.
- Your major organs like bone marrow, liver, and kidneys are working well enough (based on blood tests and kidney function).
- You are not pregnant and agree to use birth control during and for 6 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental treatment called CD19 UCAR T cells for people with severe lupus that hasn't gotten better with standard medicines. It aims to see if these special immune cells can safely and effectively control the disease.
This study tests a new medicine called CHT105 for lupus patients whose kidney disease hasn't improved with standard treatments. The medicine targets specific immune cells that may be driving the kidney damage.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
This trial tests a new cell therapy, CD19 UCAR-T cells, to see if it can help people with certain autoimmune diseases like lupus or scleroderma that haven't improved with standard treatments. It aims to reset the immune system by targeting and removing faulty B cells.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target two proteins (CD19 and BCMA) on lupus cells. It is for people with lupus nephritis (kidney inflammation) that has not improved after trying multiple standard treatments.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.